Anesthetic Considerations for Electroconvulsive Therapy, a Team Approach
Topics Covered in the presentation are:
1) History
2) Indications
3) Contraindications
4) Relative contraindications
5) Pre-Procedure Evaluation
6) Pre-Procedure Preparation
7) Anesthesia Preparation
8) Risks & Adverse Effects
9) Equipment
10) Drugs for ECT
11) Follow up Treatments
12) Other Considerations
13) Effectiveness
Learning Objectives:
- Discuss the anesthesia evaluation and management of the patient having a
- series of ECT treatments.
- Identify the possible complications a patient my experience during or after an ECT treatment.
- Identify the causes of and treatment for changes in vital signs during and after ECT.
- Discuss the psychiatry/ anesthesiology team approach to caring for the ECT patient.
System requirements for module:
Windows:
- 800 MHz Intel Pentium III processor (or equivalent) and later
- Windows 2000, Windows XP
- 256 MB RAM (1 GB recommended to run more than one Studio 8 product simultaneously)
- 1024 x 768, 16-bit display (32-bit recommended)
- 710 MB available disk space
- Audio Needed
Duration of Presentation:
50 Minutes
Target audience for this Presentation:
Active members of the PSA
Evaluation Method:
Quiz
Faculty:
Carol E. Rose, MD
Assistant Professor – Anesthesiology
Medical Director of Anesthesia Service
Western Psychiatric Institute and Clinic
University of Pittsburgh Medical Center
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Pennsylvania Medical Society and the Pennsylvania Society of Anesthesiologists, Inc. The Pennsylvania Medical Society is accredited by the ACCME to provide continuing medical education for physicians.
The Pennsylvania Medical Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physician should only claim credit commensurate with the extent of their participation in the educational activity.
Faculty and all others who have the ability to control the content of continuing medical education activities sponsored by the Pennsylvania Medical Society are expected to disclose to the audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s).
The Faculty participating in this activity has indicated that they have no real or apparent conflict of interest.
Disclaimer: The material presented here does not necessarily reflect the views of The PSA, its officers, or committee members. These materials may discuss uses and dosages for therapeutic products that have not been approved for marketing by the United States Food and Drug Administration. All readers and continuing education participants should verify all information presented before treating patients or utilizing any therapeutic product or method discussed in this educational activity.